Leptomeningeal disease and breast cancer: The importance of tumor subtype

Breast Cancer Research and Treatment

Volumn 146, Issue 3, 2014, Pages 477-486

  Abouharb, Sausan ^a   Ensor, Joe ^a   Loghin, Monica Elena ^a   Katz, Ruth ^a   Moulder, Stacy L ^a   Esteva, Francisco J ^b   Smith, Benjamin ^a   Valero, Vicente ^a   Hortobagyi, Gabriel N ^a   Melhem Bertrandt, Amal ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Leptomeningeal disease; Outcome; Tumor subtype

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTARABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MAFOSFAMIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; SODIUM IODIDE I 131; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; TRASTUZUMAB;

ADULT; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; HUMAN; LEPTOMENINGEAL DISEASE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENINX DISORDER; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; AGED; BREAST NEOPLASMS; COMPLICATION; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; MENINGEAL NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MENINGEAL NEOPLASMS; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84907598178     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3054-z     Document Type: Review

References (16)

1. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25(2):103-119. doi:10.1053/ctrv.1999.0119 (Pubitemid 29353669)
2. Aparicio A, Chamberlain MC (2002) Neoplastic meningitis. Curr Neurol Neurosci Rep 2(3):225-235
3. Jaeckle KA (2006) Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol 33(3):312-323. doi:10.1053/j.seminoncol.2006.04.016
4. Armstrong TS, Gilbert MR (2004) The treatment of neoplastic meningitis. Expert Opin Pharmacother 5(9):1929-1935. doi:10.1517/14656566.5.9.1929 (Pubitemid 39236594)
5. Hoffmann AL, Buhk JH, Strik H (2009) Neoplastic meningitis from breast cancer: feasibility and activity of long-term intrathecal liposomal Ara-C combined with dose-dense temozolomide. Anticancer Res 29(12):5191-5195
6. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, Hart AA, Benraadt J, Vecht ChJ (2004) The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 40(18):2726-2733. doi:10.1016/j.ejca.2004.08.012 (Pubitemid 39574724)
7. Rudnicka H, Niwinska A, Murawska M (2007) Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol 84(1):57-62. doi:10.1007/s11060-007-9340-4 (Pubitemid 47103444)
8. Lin NU (2010) Concordance of HER2 in primary tumor and leptomeningeal metastases: now what? Breast Cancer Res Treat 123(1):129-131. doi:10.1007/s10549-009-0720-7
9. Meriggi F, Zaniboni A (2011) Newer avenues for the treatment of leptomeningeal carcinomatosis. Cent Nerv Syst Agents Med Chem 11(1):38-44
10. Le Rhun E, Taillibert S, Zairi F, Devos P, Pierret MF, Dubois F, Assaker R, Buisset E, Bonneterre J, Baranzelli MC (2011) Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: a case-control study. J Neurooncol 105(2):309-315. doi:10.1007/s11060-011-0592-7
11. Lee S, Ahn HK, Park YH, do Nam H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH (2011) Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat 129(3):809-817. doi:10.1007/s10549-011-1682-0
12. Torrejon D, Oliveira M, Cortes J, Sanchez-Olle G, Gomez P, Bellet M, Saura C, Peg V, Rovira A, Di Cosimo S (2013) Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast 22(1):19-23. doi:10.1016/j.breast.2012.10.009
13. Jang G, Lee SS, Ahn JH, Jung KH, Lee H, Gong G, Kim HH, Ahn SD, Son BH, Ahn SH, Kim SB (2011) Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Res Treat 128(1):171-177. doi:10.1007/s10549-011-1526-y
14. Lim E, Lin NU (2012) New insights and emerging therapies for breast cancer brain metastases. Oncology 26 (7):652-659, 663
15. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112(11):2359-2367. doi:10.1002/cncr.23468
16. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR (1982) Treatment for meningeal carcinomatosis in breast cancer. Cancer 50(2):219-222 (Pubitemid 12089377)